ACAD
34.3
-0.68
-1.94%
AEMD
4.96
-0.15
-2.94%
APRI
0.342
-0.008
-2.3163%
ARNA
1.73
-0.01
-0.57%
ATEC
8.21
-0.42
-4.87%
CNAT
2.1
0.00
N/A%
CRXM
0.24
-0.03
-10.70%
CYTX
2.04
-0.08
-3.77%
DXCM
93.16
-0.75
-0.80%
GNMK
11.56
-0.14
-1.20%
HALO
11.98
0.00
N/A%
ILMN
178.47
0.00
N/A%
INNV
0.29
+0.01
+3.5357%
INO
9.44
0.00
0.00%
ISCO
1.84
-0.06
-3.16%
ISIS
57.56
0.00
N/A%
LGND
113.09
-2.69
-2.32%
LPTN
3.83
-0.06
-1.54%
MBVX
4.16
-0.56
-11.86%
MEIP
1.71
+0.02
+1.18%
MNOV
7.47
+0.37
+5.21%
MRTX
6.2
+0.32
+5.44%
MSTX
0.123
-0.004
-3.454%
NBIX
53.25
0.00
N/A%
NUVA
66.15
-0.62
-0.93%
ONCS
1.77
-0.01
-0.56%
ONVO
3.91
0.00
N/A%
OREX
3.24
-0.22
-6.36%
OTIC
17.13
-0.52
-2.95%
QDEL
22.17
-0.54
-2.38%
RCPT
231.96
0.00
N/A%
RGLS
3.42
-0.03
-0.87%
RMD
63.59
+0.34
+0.54%
SPHS
3.22
+0.26
+8.78%
SRNE
7.67
-0.1
-1.29%
TROV
4.63
-0.16
-3.34%
VICL
3.19
-0.06
-1.85%
VOLC
18
0.00
0.00%
ZGNX
10.35
-0.1
-0.96%
ACAD
34.3
-0.68
-1.94%
AEMD
4.96
-0.15
-2.94%
APRI
0.342
-0.008
-2.3163%
ARNA
1.73
-0.01
-0.57%
ATEC
8.21
-0.42
-4.87%
CNAT
2.1
0.00
N/A%
CRXM
0.24
-0.03
-10.70%
CYTX
2.04
-0.08
-3.77%
DXCM
93.16
-0.75
-0.80%
GNMK
11.56
-0.14
-1.20%
HALO
11.98
0.00
N/A%
ILMN
178.47
0.00
N/A%
INNV
0.29
+0.01
+3.5357%
INO
9.44
0.00
0.00%
ISCO
1.84
-0.06
-3.16%
ISIS
57.56
0.00
N/A%
LGND
113.09
-2.69
-2.32%
LPTN
3.83
-0.06
-1.54%
MBVX
4.16
-0.56
-11.86%
MEIP
1.71
+0.02
+1.18%
MNOV
7.47
+0.37
+5.21%
MRTX
6.2
+0.32
+5.44%
MSTX
0.123
-0.004
-3.454%
NBIX
53.25
0.00
N/A%
NUVA
66.15
-0.62
-0.93%
ONCS
1.77
-0.01
-0.56%
ONVO
3.91
0.00
N/A%
OREX
3.24
-0.22
-6.36%
OTIC
17.13
-0.52
-2.95%
QDEL
22.17
-0.54
-2.38%
RCPT
231.96
0.00
N/A%
RGLS
3.42
-0.03
-0.87%
RMD
63.59
+0.34
+0.54%
SPHS
3.22
+0.26
+8.78%
SRNE
7.67
-0.1
-1.29%
TROV
4.63
-0.16
-3.34%
VICL
3.19
-0.06
-1.85%
VOLC
18
0.00
0.00%
ZGNX
10.35
-0.1
-0.96%
Home » Archive by Category

Syndication

Patent Attorney – Organovo – San Diego, CA

September 23, 2016 – 7:39 am

Must have experience prosecuting biotechnology patents. The Patent Attorney will report directly to the company’s General Counsel and will support various…
From careerbuildergulf – Fri, 23 Sep 2016 14:39:49 GMT – View all San Diego jobs

Biocept’s Proprietary Liquid Biopsy Platform to be Featured at Two Upcoming Molecular Diagnostics Conferences

September 23, 2016 – 6:56 am

SAN DIEGO, Sept. 23, 2016 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces that Lyle Arnold, Ph.D., Chief Scientific Officer of Biocept, will present at two SelectBio conferences being held between September 26-30 in San Diego.  Dr. Arnold’s presentations will focus on Biocept’s patented Target-Selector™ technology, which uses liquid biopsy to detect and monitor tumor biomarkers to aid physicians in making treatment decisions for patients with cancer.

Dr. Arnold will present “Interrogation of Single Circulating Tumor Cells using Microchannel Enrichment” at the NGS, SCA, SMA & Mass Spec: Research to Diagnostics 2016 Conference on September 27, and “Combining CTC and ctDNA Platforms from the Same Clinical Samples to Expand Liquid Biopsy Biomarker Content” at the Liquid Biopsies and Minimally-Invasive Diagnostics 2016 Conference on September 29. 

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

Logo – http://photos.prnewswire.com/prnh/20151013/276540LOGO

 

SOURCE Biocept, Inc.

Clinical Research Associate – 12k Sign On!! – ICON Clinical Research, Inc. – San Diego, CA

September 23, 2016 – 6:00 am

This is an exciting opportunity to work within a fast paced, busy environment for a leading global provider of outsourced development services to the…From Indeed – Fri, 23 Sep 2016 13:00:33 GMT – View all San Diego jobs

Sr. Manager/Associate Director Statistical Programming – Xencor – San Diego, CA

September 23, 2016 – 5:08 am

Is an innovative biotechnology company located in the Los Angeles area (near Pasadena) and in San Diego. We have an expanding clinical pipeline of promising…From Xencor – Fri, 23 Sep 2016 12:08:41 GMT – View all San Diego jobs

Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More

September 23, 2016 – 3:30 am

Another biopharma executive went before Congress to explain drug price hikes. Unlike Martin Shkreli, Mylan CEO Heather Bresch actually answered questions. Taking heat over the EpiPen scandal, she…

[[Click headline to continue reading.]]

In Turnaround Saga, Ignyta Nears Crucial Phase in Cancer Drug Trial

September 23, 2016 – 1:40 am

Biotech CEO Jonathan Lim co-founded Ignyta in 2011 to commercialize a new approach to diagnosing and treating rheumatoid arthritis, based on discoveries that showed how changes in methyl group…

[[Click headline to continue reading.]]

Senior/Principal Scientist – BioPhase Solutions – San Diego, CA

September 23, 2016 – 1:25 am

We are currently looking for a Senior/Principal Scientist to work for a leading San Diego biotechnology company….From BioPhase Solutions – Fri, 23 Sep 2016 08:25:50 GMT – View all San Diego jobs

Principal Scientist – BioPhase Solutions – San Diego, CA

September 23, 2016 – 1:25 am

We are currently looking for a Principal Scientist to work for a leading San Diego biotechnology company….From BioPhase Solutions – Fri, 23 Sep 2016 08:25:49 GMT – View all San Diego jobs

Principal Research Scientist/Research Advisor-Biotherapeutics – Eli Lilly and Company – San Diego, CA

September 22, 2016 – 10:18 pm

We have an opportunity for a creative and highly motivated Scientist to join our team as a Leader in our Biotechnology discovery and engineering group….From BioSpace.com – Fri, 23 Sep 2016 05:18:49 GMT – View all San Diego jobs

Clinical Sales Specialist, IBD San Diego, CA (S0110) – Takeda Pharmaceuticals – San Diego, CA

September 22, 2016 – 9:45 pm

5years direct selling experience to healthcare professionals in thepharmaceutical, biotech, device or healthcare industry that has included:….From Takeda Pharmaceuticals – Fri, 23 Sep 2016 04:45:06 GMT – View all San Diego jobs